Program
cabotegravir
Also written as “CAB LA”, “GSK1265744” and “Cabotegravir - Injectable Suspension (CAB LA)”.
Its studies are mostly in HIV Infections · Infections · Acquired Immunodeficiency Syndrome · HIV-Associated Lipodystrophy Syndrome, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 408 open or running | phase 4since May 10, 2022 | Apr 10, 2008 | Mar 8, 2027phase 1 · NCT06786520 |
| Johnson & Johnson | 10 open or running | phase 1since Nov 2, 2021 | Nov 2, 2021 | none ahead |
Also a collaborator on its studies: ppd-development-lp and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 26 studies since Apr 10, 2008.
- May 18, 2020Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT04399551 · 437 enrolled · Belgium, France, Germany and more
- Jul 20, 2020Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT04484337 · 138 enrolled · United States, New Zealand
- Sep 1, 2020Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT04542070 · 687 enrolled · United States, Australia, Austria and more
- Nov 2, 2021Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT05112939 · 126 enrolled · United States, Netherlands
- May 10, 2022Phase 4 study in HIV InfectionsGlaxoSmithKline · NCT05374525 · 287 enrolled · United States
- Aug 22, 2022Phase 4 study in HIV InfectionsGlaxoSmithKline · NCT05514509 · 295 enrolled · United States
- May 31, 20232 phase 3 studies in Acquired Immunodeficiency SyndromeGlaxoSmithKline · NCT05896761, NCT05896748
- Jun 13, 2023Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT05917509 · 171 enrolled · United States, Argentina, Canada and more
- Aug 31, 2023Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT06033547 · 56 enrolled · United States
- Nov 10, 2023Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT06134362 · 2,998 enrolled · Argentina, Botswana, Brazil and more
- Dec 17, 2024Phase 2 study in HIV InfectionsGlaxoSmithKline · NCT06741397 · 229 enrolled · United States, Puerto Rico
- Jan 15, 2025Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT06786520 · 69 enrolled · United States
- Apr 11, 2025Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT06970223 · 65 enrolled · United States
- Nov 27, 2025Phase 2 study in HIV InfectionsGlaxoSmithKline · NCT07275606 · 44 planned · South Africa
Ahead
- Mar 8, 2027Primary completion: phase 1 study in HIV InfectionsGlaxoSmithKline · NCT06786520
- Mar 14, 2029Primary completion: phase 3 study in HIV InfectionsGlaxoSmithKline · NCT06134362
- Oct 10, 2029Primary completion: phase 2 study in HIV InfectionsGlaxoSmithKline · NCT07275606
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 integrase inhibitor; Human immunodeficiency virus type 1 integrase inhibitor”ChEMBL 37, by rule
Studies
All 41 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07275606HIV Infections · South Africa | 2 | Recruiting | GlaxoSmithKline | Oct 10, 2029 | 44 |
| NCT06970223HIV Infections · United States | 1 | Active, not recruiting | GlaxoSmithKline | Jul 15, 2025 | 65 |
| NCT06786520HIV Infections · United States | 1 | Active, not recruiting | GlaxoSmithKline | Mar 8, 2027 | 69 |
| NCT06741397HIV Infections · United States, Puerto Rico | 2 | Active, not recruiting | GlaxoSmithKline | Sep 9, 2026 | 229 |
| NCT06134362HIV Infections · Argentina, Botswana, Brazil and more | 3 | Active, not recruiting | GlaxoSmithKline | Mar 14, 2029 | 2,998 |
| NCT06033547HIV Infections · United States | 1 | Completed | GlaxoSmithKline | Jul 25, 2025 | 56 |
| NCT05917509HIV Infections · United States, Argentina, Canada and more | 3 | Completed | GlaxoSmithKline | Sep 16, 2025 | 171 |
| NCT05896761Acquired Immunodeficiency Syndrome · United States, Argentina, Canada and more | 3 | Completed | GlaxoSmithKline | Aug 23, 2022 | 118 |
| NCT05896748Acquired Immunodeficiency Syndrome · United States, Canada, Japan and more | 3 | Completed | GlaxoSmithKline | Sep 14, 2023 | 94 |
| NCT05514509HIV Infections · United States | 4 | Completed | GlaxoSmithKline | Sep 2, 2025 | 295 |
| NCT05374525HIV Infections · United States | 4 | Completed | GlaxoSmithKline | Aug 8, 2024 | 287 |
| NCT05112939Healthy · United States, Netherlands | 1 | Completed | Johnson & Johnson | May 23, 2024 | 126 |
| NCT04542070HIV Infections · United States, Australia, Austria and more | 3 | Completed | GlaxoSmithKline | Jul 13, 2022 | 687 |
| NCT04484337HIV Infections · United States, New Zealand | 1 | Completed | GlaxoSmithKline | May 5, 2023 | 138 |
| NCT04399551HIV Infections · Belgium, France, Germany and more | 3 | Completed | GlaxoSmithKline | Mar 7, 2022 | 437 |
| NCT04371380HIV Infections · United States | 1 | Completed | GlaxoSmithKline | Dec 26, 2021 | 15 |
| NCT03639311HIV Infections · United States, Canada | 2 | Completed | GlaxoSmithKline | Dec 11, 2019 | 97 |
| NCT03299049HIV Infections · United States, Argentina, Australia and more | 3 | Active, not recruiting | GlaxoSmithKline | Jun 6, 2019 | 1,049 |
| NCT03149848Infections · United Kingdom | 1 | Completed | GlaxoSmithKline | Sep 6, 2017 | 15 |
| NCT02951052Infections · United States, Argentina, Australia and more | 3 | Active, not recruiting | GlaxoSmithKline | May 29, 2018 | 618 |
| NCT02938520HIV Infections · United States, Canada, France and more | 3 | Active, not recruiting | GlaxoSmithKline | Aug 30, 2018 | 631 |
| NCT02799264Infections · United States | 1 | Completed | GlaxoSmithKline | Aug 2016 | 24 |
| NCT02478463Infections · United States | 1 | Completed | GlaxoSmithKline | Jul 25, 2019 | 19 |
| NCT02354950HIV Infections · United States | 1 | Completed | GlaxoSmithKline | Sep 16, 2016 | 16 |
| NCT02354937Infections · United States | 1 | Completed | GlaxoSmithKline | Nov 1, 2016 | 16 |
| NCT02345707Infections · United States | 1 | Completed | GlaxoSmithKline | Jun 2015 | 37 |
| NCT02159131Infections · United Kingdom | 1 | Completed | GlaxoSmithKline | Dec 2014 | 20 |
| NCT02120352Infections · United States, Canada, France and more | 2 | Completed | GlaxoSmithKline | Aug 13, 2015 | 309 |
| NCT02059031Infections · United States | 1 | Completed | GlaxoSmithKline | Jun 2014 | 24 |
| NCT02027454Infections · United States | 1 | Completed | GlaxoSmithKline | Jun 2014 | 42 |
| NCT01848340HIV-Associated Lipodystrophy Syndrome · United States | 1 | Completed | GlaxoSmithKline | Jul 2013 | 16 |
| NCT01754116Infections · United States | 1 | Completed | GlaxoSmithKline | Apr 2014 | 43 |
| NCT01648257Infections · United States | 1 | Completed | GlaxoSmithKline | Nov 2012 | 18 |
| NCT01641809Infections · United States, Canada | 2 | Completed | GlaxoSmithKline | Oct 10, 2013 | 244 |
| NCT01593046Infections · United States | 1 | Completed | GlaxoSmithKline | Nov 2013 | 43 |
| NCT01467531Infections · United States | 1 | Completed | GlaxoSmithKline | Feb 2012 | 28 |
| NCT01756131Infections | 1 | Completed | GlaxoSmithKline | Dec 2012 | 72 |
| NCT00920426Infections · United States | 2 | Completed | GlaxoSmithKline | Aug 13, 2009 | 9 |
| NCT00920296Infections · United States | 1 | Completed | GlaxoSmithKline | Sep 2009 | 12 |
| NCT00812318HIV Infections · United States | 1 | Completed | GlaxoSmithKline | Aug 2008 | 45 |
| NCT00659191HIV Infections · United States | 1 | Completed | GlaxoSmithKline | Nov 2008 | 58 |
How it is read
Names in the registry
- “CAB LA”, 7 entries
- “GSK1265744”, 5 entries
- “Cabotegravir - Injectable Suspension (CAB LA)”, 3 entries
- “Cabotegravir (CAB) tablet”, 2 entries
- “Cabotegravir Injectable Suspension”, 2 entries
Conditions, from the studies’ own filings
- HIV Infections, 25 studies
- Infections, 12 studies
- Acquired Immunodeficiency Syndrome, 2 studies
- HIV-Associated Lipodystrophy Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.